DiaMedica Therapeutics Enters Sales Agreement with TD Securities

Diamedica Therapeutics ( (DMAC) ) just unveiled an announcement.

On August 12, 2025, DiaMedica Therapeutics Inc. entered into a Sales Agreement with TD Securities (USA) LLC, allowing the company to offer and sell its common shares through TD Cowen, with a potential aggregate offering amount of up to $100 million. This agreement, which involves an ‘at the market offering’, outlines that TD Cowen will act as the sales agent, earning up to 3% of the gross proceeds from the sales. The proceeds from these sales will depend on the number of shares sold and their offering price, with the company agreeing to cover certain costs and liabilities for TD Cowen. The sales will be conducted under a shelf registration statement filed with the SEC, which has not yet been declared effective.

The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.

Spark’s Take on DMAC Stock

According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.

Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.

To see Spark’s full report on DMAC stock, click here.

More about Diamedica Therapeutics

Average Trading Volume: 292,116

Technical Sentiment Signal: Buy

Current Market Cap: $236.7M

For an in-depth examination of DMAC stock, go to TipRanks’ Overview page.